Huang, Y.Q., Tan, Z.Y., Luo, L., Yang, H., Tong, C.M., Chen, W.F., Huang, T.Y. and Liu, R.L. (2014) The Polymorphism and Transformation of (3aRS,4RS,7RS,7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyi-soindoline-1,3-dione (SU2162)—A Novel Anticancer Compound. Journal of Crystallization Process and Technology, 4, 27-30.
http://dx.doi.org/10.4236/jcpt.2014.41004

has been cited by the following article:

• TITLE: Preparation and Characterization of Two Polymorphs of (3aRS,4RS,7RS,7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162) with PXRD and DSC

  AUTHORS: Wenfei Chen, Zaiyou Tan, Lin Luo, Ruisi Yan, Hui Yang, Chunmei Tong, Yuqing Huang, Tingyu Huang, Yang Yang, Ruonan Wang

  KEYWORDS: SU2162, Crystal Form, DSC, PXRD

  JOURNAL NAME: Advances in Materials Physics and Chemistry, Vol.5 No.1, January 13, 2015

  ABSTRACT: Objective: To develop the characterization of the polymorphs and the best preparation method of two forms of the title compound (SU2162). After SU2162 was prepared in accordance with the patent process, the crystal form I was recrystallized by ethyl acetate and the crystal form II was obtained by the recrystal in acetone. And the two crystal forms were characterized with differential scanning calorimetry (DSC) and X-ray powder diffraction (PXRD). The melting point of crystal form I (triclinic) is at 158°C, and the melting point of crystal form II (monoclinic) is at 163°C. The PXRD studies of the two crystalline samples indicate that they have the distinct diffraction patterns. The method herein can be stably prepared for the two crystal forms of the title compound.